ONCOCYTE CORP's ticker is OCX and the CUSIP is 68235C107. A total of 47 filers reported holding ONCOCYTE CORP in Q2 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $230 | -35.2% | 1,000 | 0.0% | 0.00% | – |
| Q1 2023 | $355 | +10.6% | 1,000 | 0.0% | 0.00% | – |
| Q4 2022 | $321 | -67.9% | 1,000 | 0.0% | 0.00% | – |
| Q3 2022 | $1,000 | 0.0% | 1,000 | 0.0% | 0.00% | – |
| Q2 2022 | $1,000 | 0.0% | 1,000 | 0.0% | 0.00% | – |
| Q1 2022 | $1,000 | -50.0% | 1,000 | 0.0% | 0.00% | -100.0% |
| Q4 2021 | $2,000 | -50.0% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $4,000 | -33.3% | 1,000 | 0.0% | 0.00% | -50.0% |
| Q2 2021 | $6,000 | +20.0% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $5,000 | +150.0% | 1,000 | 0.0% | 0.00% | +100.0% |
| Q4 2020 | $2,000 | +100.0% | 1,000 | 0.0% | 0.00% | – |
| Q2 2020 | $1,000 | -50.0% | 1,000 | 0.0% | 0.00% | -100.0% |
| Q1 2020 | $2,000 | 0.0% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $2,000 | -66.7% | 1,000 | -66.7% | 0.00% | -66.7% |
| Q3 2019 | $6,000 | -25.0% | 3,000 | -9.1% | 0.00% | -25.0% |
| Q2 2019 | $8,000 | -38.5% | 3,300 | 0.0% | 0.00% | -55.6% |
| Q1 2019 | $13,000 | – | 3,300 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 17,349,945 | $25,851,000 | 1.86% |
| Defender Capital, LLC. | 2,562,130 | $4,001,000 | 1.39% |
| PURA VIDA INVESTMENTS, LLC | 12,223,953 | $18,214,000 | 0.59% |
| Penbrook Management LLC | 578,150 | $861,000 | 0.56% |
| ACT CAPITAL MANAGEMENT, LLC | 330,000 | $492,000 | 0.52% |
| Orbimed Advisors | 3,493,800 | $5,206,000 | 0.08% |
| CALIBER WEALTH MANAGEMENT, LLC | 75,120 | $112,000 | 0.07% |
| Fort Sheridan Advisors LLC | 135,000 | $201,000 | 0.06% |
| AWM Investment Company, Inc. | 241,867 | $360,000 | 0.05% |
| WEALTH EFFECTS LLC | 49,000 | $73,000 | 0.03% |